Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping.
about
Pathogenesis of human immunodeficiency virus infectionHGP-30, a synthetic analogue of human immunodeficiency virus (HIV) p17, is a target for cytotoxic lymphocytes in HIV-infected individuals.Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells.Exploiting Natural Cross-reactivity between Human Immunodeficiency Virus (HIV)-1 p17 Protein and Anti-gp41 2F5 Antibody to Induce HIV-1 Neutralizing Responses In Vivo.The GAG precursor of simian immunodeficiency virus assembles into virus-like particlesProduction of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein.HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor.Identification of a protective CD4+ T-cell epitope in p15gag of Friend murine leukemia virus and role of the MA protein targeting the plasma membrane in immunogenicityPrincipal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag ProteinA highly conserved residue in the C-terminal helix of HIV-1 matrix is required for envelope incorporation into virus particlesProtective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus.Characterization of human immunodeficiency virus type 1 matrix revertants: effects on virus assembly, Gag processing, and Env incorporation into virions.Wash-free, electrochemical platform for the quantitative, multiplexed detection of specific antibodiesAntibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles.Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein, p17gag: identification of epitopes exposed at the surfaces of infected cells.A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization.Monoclonal antibodies and chemiluminescence immunoassay for detection of the surface protein of human T-cell lymphotropic virus.Chimeric peptide beacons: a direct polypeptide analog of DNA molecular beaconsChimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodiesExamination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.A neutralizing monoclonal antibody previously mapped exclusively on human immunodeficiency virus type 1 gp41 recognizes an epitope in p17 sharing the core sequence IEEE.A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum.The human immunodeficiency virus (HIV) gag gene product p18 is responsible for enhanced fusogenicity and host range tropism of the highly cytopathic HIV-1-NDK strain.Relation between humoral responses to HIV gag and env proteins at seroconversion and clinical outcome of HIV infection.Establishment of a foreign antigen secretion system in mycobacteria.Peptide beacons: a new design for polypeptide-based optical biosensors.
P2860
Q24634681-D522F633-2C3D-49B6-A2E9-BF9351906A27Q33788369-D6AC4723-5955-462D-9DAA-5D89CD94FCBBQ33851786-A3140121-45B6-49B0-AE95-D4F0677B0364Q33855697-37382D29-1DF7-4167-8C69-62473F9FBA70Q34046090-B3445D76-9D52-44C3-8B1A-74AA9B991E6DQ34097650-865EB4CB-AC5F-4AEF-AF2C-55FF38382D88Q34098372-51ACA393-9E5E-4714-BCE2-311879B33F11Q34186587-AA6483C1-9669-49A0-92BA-042311437969Q34301897-A320DDCF-CB9E-4BF2-A4B6-E7EA2737B2FFQ35726702-57AB8704-2FD2-4CCA-A463-D1C67C4C4DB5Q35826475-9B99DF2B-320C-4838-888B-883F5F30CEFBQ35851163-FE644C74-0DEB-4163-921C-8044E49E53FEQ35886475-EF507DAD-256B-46F8-91CA-B8485C6C38A1Q36470897-B9F13F47-3345-4099-9616-C1D8E13E3895Q36634341-34B9E859-77F1-49E9-A1AA-5D4E77A043C3Q36781270-E396EA00-BC20-4FEC-9B32-418DE9F1E7C7Q36793670-EECAA5B6-C99E-4341-BEBC-251F20125010Q36797252-6B6B974F-8AAE-4B5D-8F7E-209E40AAE243Q36797706-94980A9F-7A0A-4C57-9609-E43F1A53046EQ36801560-D83CF809-7B80-4F7A-A5BB-5D3388BE4979Q37115853-AE9B84A1-C7B2-44CB-9B4C-B69E099B8BE9Q37217475-81E2E97E-AA40-49AA-9795-0FC212214E9DQ37284795-60BDDC01-8EAD-4F0B-9841-0BCDAFC673E1Q39579497-F62F13CC-8CE1-4BD3-8DAB-CB1D6002BEC0Q39878801-81F954E4-DF08-42BE-980A-64DB6752DD34Q40046621-A193777F-03FF-460F-805E-61918E99806AQ40060923-342ABD16-80CB-4300-A898-246A25CC19FDQ40069582-A29B5DAA-28FC-42D3-8717-6A9ADFC69F48Q40429250-B355AC9C-C8A9-4FC0-99F1-E07E26210479Q41998158-AD496A38-2871-4A3B-BE3C-91143EA2DB07
P2860
Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Human immunodeficiency virus t ...... erization and epitope mapping.
@ast
Human immunodeficiency virus t ...... erization and epitope mapping.
@en
type
label
Human immunodeficiency virus t ...... erization and epitope mapping.
@ast
Human immunodeficiency virus t ...... erization and epitope mapping.
@en
prefLabel
Human immunodeficiency virus t ...... erization and epitope mapping.
@ast
Human immunodeficiency virus t ...... erization and epitope mapping.
@en
P2093
P2860
P1433
P1476
Human immunodeficiency virus t ...... erization and epitope mapping.
@en
P2093
F W Ruscetti
L D Papsidero
P2860
P304
P407
P577
1989-01-01T00:00:00Z